PL2046341T3 - Kompozycje i sposoby leczenia cukrzycy i dysfunkcji neuropsychologicznej - Google Patents

Kompozycje i sposoby leczenia cukrzycy i dysfunkcji neuropsychologicznej

Info

Publication number
PL2046341T3
PL2046341T3 PL07788108T PL07788108T PL2046341T3 PL 2046341 T3 PL2046341 T3 PL 2046341T3 PL 07788108 T PL07788108 T PL 07788108T PL 07788108 T PL07788108 T PL 07788108T PL 2046341 T3 PL2046341 T3 PL 2046341T3
Authority
PL
Poland
Prior art keywords
compositions
methods
treating diabetes
neuropsychological dysfunction
neuropsychological
Prior art date
Application number
PL07788108T
Other languages
English (en)
Inventor
Michel Polak
Paul Czernichow
Original Assignee
Assistance Publique - Hôpitaux De Paris
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux De Paris, Universite Paris Descartes filed Critical Assistance Publique - Hôpitaux De Paris
Publication of PL2046341T3 publication Critical patent/PL2046341T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL07788108T 2006-08-02 2007-08-01 Kompozycje i sposoby leczenia cukrzycy i dysfunkcji neuropsychologicznej PL2046341T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291256A EP1884244A1 (en) 2006-08-02 2006-08-02 Potassium channel ligands for treating diabetes and neuropsychological dysfunction

Publications (1)

Publication Number Publication Date
PL2046341T3 true PL2046341T3 (pl) 2017-02-28

Family

ID=37496865

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07788108T PL2046341T3 (pl) 2006-08-02 2007-08-01 Kompozycje i sposoby leczenia cukrzycy i dysfunkcji neuropsychologicznej

Country Status (13)

Country Link
US (2) US8354452B2 (pl)
EP (2) EP1884244A1 (pl)
JP (1) JP5159779B2 (pl)
AU (1) AU2007280476B2 (pl)
CA (1) CA2657342C (pl)
DK (1) DK2046341T3 (pl)
ES (1) ES2589953T3 (pl)
HU (1) HUE029479T2 (pl)
IL (1) IL196561A (pl)
NZ (1) NZ574892A (pl)
PL (1) PL2046341T3 (pl)
PT (1) PT2046341T (pl)
WO (1) WO2008015226A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095548A2 (es) * 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
BR112013018374A2 (pt) 2011-01-25 2016-10-11 Monell Chemical Senses Centre composições e métodos para fornecer ou modular o sabor doce e métodos para rastrear os mesmos
EP2520298A1 (en) * 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
US20130273181A1 (en) * 2012-03-07 2013-10-17 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for diagnosing and treating muscle myopathy disorders
US9879020B2 (en) 2012-09-21 2018-01-30 Uwm Research Foundation, Inc. GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
EP3619222A4 (en) 2017-05-05 2021-02-17 Nino Sorgente METHODS AND COMPOSITIONS FOR IMPROVING EYE HEALTH

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051361A1 (en) * 2000-05-15 2001-12-13 Wei Shao Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
CA2487416A1 (en) * 2002-06-10 2003-12-18 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes
ES2352203T3 (es) 2004-06-23 2011-02-16 Neurotec Pharma, S.L. Compuesto para uso en el diagnóstico de daño agudo del sistema nervioso central.
ATE487484T1 (de) * 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür

Also Published As

Publication number Publication date
PT2046341T (pt) 2016-08-31
US8354452B2 (en) 2013-01-15
US20090306212A1 (en) 2009-12-10
HUE029479T2 (en) 2017-02-28
EP2046341A1 (en) 2009-04-15
WO2008015226A1 (en) 2008-02-07
AU2007280476A1 (en) 2008-02-07
JP2009545562A (ja) 2009-12-24
CA2657342A1 (en) 2008-02-07
CA2657342C (en) 2016-04-12
JP5159779B2 (ja) 2013-03-13
IL196561A (en) 2015-08-31
IL196561A0 (en) 2009-11-18
AU2007280476B2 (en) 2013-01-31
US20130184293A1 (en) 2013-07-18
NZ574892A (en) 2012-11-30
EP2046341B1 (en) 2016-07-13
DK2046341T3 (en) 2016-08-29
ES2589953T3 (es) 2016-11-17
EP1884244A1 (en) 2008-02-06

Similar Documents

Publication Publication Date Title
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
HK1125868A1 (en) Compositions and methods for treating bone
IL186963A0 (en) Methods and compositions for treating pain
EP2076116A4 (en) COMPOSITIONS, METHODS AND DEVICES FOR THE TREATMENT OF LIVER DISEASES
EP1890712A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
HK1121952A1 (en) Methods and compositions for treating conditions
EP2015765A4 (en) METHODS AND COMPOSITIONS FOR TREATING CONDITIONS
ZA200900140B (en) Methods and compositions for treating biofilms
IL198723A0 (en) Methods and compositions for therapeutic treatment
IL196561A0 (en) Compositions and methods for treating diabetes and neuropsychological dysfunction
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
EP2124968A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE ATROPHY
IL196411A0 (en) Anti-cocaine compositions and treatment
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
GB0718918D0 (en) Compositions and methods for treating skin conditions
HK1129596A1 (en) Methods and compositions for treating disease
GB0601950D0 (en) Compositions and methods of treating diabetes
IL185555A0 (en) Method and composition for treating diabetes
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP1962882A4 (en) COMPOSITIONS AND METHOD FOR TREATING DIABETES
HU0500947D0 (en) Composition for treatment of paradontosis
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
GB0620693D0 (en) Composition and methods for the treatment of degenerative disease
GB0618309D0 (en) Compositions and methods for the treatment of disease
ZA200807049B (en) Compositions and methods for treating collagen-mediated diseases